Source: Healio News
Once weekly selinexor, carfilzomib and dexamethasone was highly active and yielded deep responses in patients with heavily pretreated multiple myeloma, according to data presented at the virtual ASCO Annual Meeting.
“In patients that we treated at the recommended phase 2 dose, we achieved a response, which was kind of impressive, close to 80% and we had one-third of patients achieving a very good partial response,” Cristina Gasparetto, MD, director of the multiple myeloma program at Duke University, told Healio in a video interview.